



World Health
Organization



Immune Correlates of Protection Against Influenza A Viruses in Support of Pandemic Vaccine Development

December 10 - 11, 2007,

Bethesda, MD, USA

Introduction and Welcome

- Organizing Committee
- Announcements
- Introductory Remarks from FDA/CBER, NIH/NIAID and WHO
 - Jesse L. Goodman, MD, MPH
 - Director, Center for Biologics Evaluation & Research/FDA
 - Anthony S. Fauci, MD
 - Director, National Institute of Allergy & Infectious Diseases/NIH
 - David Wood, PhD
 - Coordinator, Quality Safety & Standards/WHO

Organizing Committee

- **Maryna Eichelberger, PhD**
 - Principal Investigator, US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review/Division of Viral Products
- **Hana Golding, PhD**
 - Chief, Lab of Retrovirus Research, US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review/Division of Viral Products
- **Maureen Hess, MPH, RD**
 - Science Policy Analyst, US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review
- **Jerry Weir, PhD**
 - Director, Division of Viral Products, US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review
- **Catherine J. Luke PhD**
 - Staff Scientist (Core), National Institutes of Health, National Institute of Allergy and Infectious Diseases/ Laboratory of Infectious Diseases
- **Kanta Subbarao, MD, MPH**
 - Senior Investigator, National Institutes of Health, National Institute of Allergy and Infectious Diseases/Laboratory of Infectious Diseases
- **Martin Friede, PhD**
 - Scientific Officer, World Health Organization
- **David Wood, PhD**
 - Coordinator, Quality Safety and Standards/IVB, World Health Organization

Announcements

- All - Use the microphones at all times
 - Workshop is being webcast
- Speakers - Load slides before your session
- All - Submit ideas for panel discussion at the end of Day 2

Goals of the Workshop

- Identify the gaps in our knowledge and abilities in addressing the unique challenges encountered in the development and evaluation of vaccines intended to protect against pandemic influenza
- Facilitate implementation of a global research agenda to improve efficacy assessment of pandemic influenza vaccines

Agenda

- Four Sessions
 - current knowledge regarding correlates of protection against seasonal influenza
 - immune responses to avian influenza infections and vaccines for novel influenza viruses in humans
 - assays to evaluate vaccine immunogenicity
 - evaluation of avian influenza vaccine efficacy
- Panel Discussion at the end of day 2
 - ***Submit comments/questions/issues for discussion to one of the organizing committee members or chairpersons of one of the 4 sessions***

Welcome